Literature DB >> 1391697

Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors.

V Gorgoulis1, D Aninos, C Priftis, C Evagelopoulou, A Karameris, P Kanavaros, D A Spandidos.   

Abstract

Immunohistochemical study of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR) and transforming growth factor-alpha (TGF-alpha) expression was performed on paraffin-embedded tissue specimens of 12 follicular carcinomas, 15 papillary carcinomas and 15 adenomas of the thyroid gland. The tumors were placed in one of the following eight groups, according to the results of EGF, TGF-alpha and EGFR expression: group 1: none, group 2: only EGFR, group 3: EGFR and TGF-alpha, group 4: EGFR and EGF, group 5: TGF-alpha, and EGF, group 6: all three, group 7: only TFG-alpha and, finally, group 8: only EGF. Statistical analysis of the results revealed that the ratio of thyroid carcinomas with lymph node metastasis was significantly higher in groups 3 and 6 for follicular carcinomas (P less than 0.01) and in groups 4, 5 and 6 for papillary carcinomas (P less than 0.01). These results suggest that thyroid carcinomas expressing the systems EGF/EGFR, TGF-alpha/EGFR or TGF-alpha/EGF/EGFR display pathologic features of more aggressive disease. Furthermore, the synchronous expression of EGF, TGF-alpha and EGFR indicates that these carcinomas may regulate their growth by an autocrine and/or paracrine mechanism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391697

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  7 in total

1.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

2.  Thyroid cancer: emerging role for targeted therapies.

Authors:  Jennifer A Sipos; Manisha H Shah
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

3.  Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.

Authors:  Le Zhao; Xiao-Yun Zhu; Rong Jiang; Man Xu; Ni Wang; George G Chen; Zhi-Min Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.

Authors:  Debora Degl'Innocenti; Chiara Alberti; Giancarlo Castellano; Angela Greco; Claudia Miranda; Marco A Pierotti; Ettore Seregni; Maria Grazia Borrello; Silvana Canevari; Antonella Tomassetti
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

5.  RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Authors:  Michelle Croyle; Nagako Akeno; Jeffrey A Knauf; Doriano Fabbro; Xu Chen; Jacqueline E Baumgartner; Heidi A Lane; James A Fagin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

6.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

7.  Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells.

Authors:  Ichiro Ota; Shigeki Higashiyama; Takashi Masui; Katsunari Yane; Hiroshi Hosoi; Nariaki Matsuura
Journal:  Oncol Rep       Date:  2013-08-06       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.